儿童癌症试验中生物靶向药物的神经毒性。
Neurotoxicity of biologically targeted agents in pediatric cancer trials.
机构信息
Brain Tumor Institute, Children's National Medical Center, Washington, DC, USA.
出版信息
Pediatr Neurol. 2012 Apr;46(4):212-21. doi: 10.1016/j.pediatrneurol.2012.02.006.
Biologically targeted agents offer the promise of delivering specific anticancer effects while limiting damage to healthy tissue, including the central and peripheral nervous systems. During the past 5-10 years, these agents were examined in preclinical and adult clinical trials, and are used with increasing frequency in children with cancer. This review evaluates current knowledge about neurotoxicity from biologically targeted anticancer agents, particularly those in pediatric clinical trials. For each drug, neurotoxicity data are reviewed in adult (particularly studies of brain tumors) and pediatric studies when available. Overall, these agents are well tolerated, with few serious neurotoxic effects. Data from younger patients are limited, and more neurotoxicity may occur in the pediatric population because these agents target pathways that control not only tumorigenesis but also neural maturation. Further investigation is needed into long-term neurologic effects, particularly in children.
生物靶向药物在为健康组织（包括中枢和周围神经系统）提供特定抗癌作用的同时，限制了对其的损伤，带来了新的希望。在过去的 5-10 年中，这些药物在临床前和成人临床试验中得到了检验，并越来越频繁地用于儿童癌症的治疗。本综述评估了目前关于生物靶向抗癌药物引起的神经毒性的知识，特别是儿科临床试验中的神经毒性。对于每种药物，都根据成人（特别是脑肿瘤研究）和儿科研究（如果有的话）评估神经毒性数据。总的来说，这些药物耐受性良好，仅有少数严重的神经毒性作用。来自年轻患者的数据有限，儿科人群中可能会发生更多的神经毒性，因为这些药物针对的是不仅控制肿瘤发生而且控制神经成熟的途径。需要进一步研究长期的神经影响，特别是在儿童中。
Zotero 插件